Literature DB >> 14616591

The provision and practice of renal replacement therapy on adult intensive care units in the United Kingdom.

S E Wright1, A Bodenham, A I K Short, J H Turney.   

Abstract

This study surveyed the availability and current practice of renal replacement therapy on adult general intensive care units in the United Kingdom. Questionnaires were returned from 236 units (89%). Renal replacement therapy was provided by 212 (90%) of responding units, treating 9442 patients per year. Renal physicians were involved in the initiation and prescription of treatment in 22 (11%) units. Ninety-one units (43%) had no step down facility on-site for those patients still requiring renal replacement therapy but no longer requiring intensive care. Continuous techniques are used by the majority of units, most commonly, continuous veno-venous haemofiltration, with an ultrafiltration rate of 2000 ml.h-1. Fifty-eight units (28%) use haemofiltration as adjuvant treatment in septic shock. The provision and practice of renal replacement therapy is now an integral part of intensive care medicine in the United Kingdom.

Entities:  

Mesh:

Year:  2003        PMID: 14616591     DOI: 10.1046/j.1365-2044.2003.03449.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  3 in total

1.  Heparin algorithm for anticoagulation during continuous renal replacement therapy.

Authors:  Marlies Ostermann; Helen Dickie; Linda Tovey; David Treacher
Journal:  Crit Care       Date:  2010-05-27       Impact factor: 9.097

Review 2.  Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury.

Authors:  Anish Kumar; Narinder Pal Singh
Journal:  Indian J Crit Care Med       Date:  2015-02

3.  Outcomes Associated With Intensive Care and Organ Support Among Patients With COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Sahar Leazer; Jacob Collen; Karl Alcover; Erin Tompkins; Shiva Ambardar; Rhonda J Allard; Brian Foster; Ryan McNutt; Matthew Leon; Zachary Haynes; Makala Bascome; Matthias Williams; Jessica Bunin; Patrick G O'Malley; Lisa K Moores; Kevin K Chung
Journal:  Mil Med       Date:  2022-05-27       Impact factor: 1.563

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.